$CRBP BIO STOCK >200 MA Break @ 7.08 > Median Analyst Target 26+
$CRBP BIO STOCK >200 MA Break @ 7.08 > Median Analyst Target 26+
Chart is setting up with the 200 MA break for a early set up to the Golden Cross, as the 50 MA is edging up. The stock will Blue Sky with a 11 break. Most Analysts have a target over 26 +.
Fundamental Catalysts
With Data coming and potential approvals could be " the excuse" to what the chart is telling us. With a median target of 26+ puts tremendous upside with limited downside here.
I expect this to be rich with catalysts, data points, and potential approvals till years end.
The Phase 2 -3 studies
dermatomyositis and lupus
cystic fibrosis
systemic sclerosis
https://seekingalpha.com/article/4097385-corbus-shining-light-rare-diseases
Chart is setting up with the 200 MA break for a early set up to the Golden Cross, as the 50 MA is edging up. The stock will Blue Sky with a 11 break. Most Analysts have a target over 26 +.
Fundamental Catalysts
With Data coming and potential approvals could be " the excuse" to what the chart is telling us. With a median target of 26+ puts tremendous upside with limited downside here.
I expect this to be rich with catalysts, data points, and potential approvals till years end.
The Phase 2 -3 studies
dermatomyositis and lupus
cystic fibrosis
systemic sclerosis
https://seekingalpha.com/article/4097385-corbus-shining-light-rare-diseases